Related Experiment Videos

Arginine intake and risk of coronary heart disease mortality in elderly men

C M Oomen1, M J van Erk, E J Feskens

  • 1Department of Chronic Diseases Epidemiology, National Institute of Public Health and the Environment, Bilthoven, the Netherlands. claudia.oomen@rivm.nl

Insights

Dietary intake of the amino acid arginine did not reduce coronary heart disease risk in elderly men. This study found no association between arginine consumption and reduced mortality from heart disease.

Area of Science:

  • Cardiovascular Science
  • Nutritional Epidemiology

Background:

  • Atherosclerosis involves impaired endothelial function and increased platelet activation.
  • Arginine, a precursor to nitric oxide (NO), was hypothesized to mitigate these effects.

Purpose of the Study:

  • To investigate the association between dietary arginine intake and coronary heart disease (CHD) risk in elderly men.

Main Methods:

  • A population-based cohort study of 806 elderly men (aged 64-84) followed for 10 years.
  • Dietary intake assessed using the cross-check dietary history method.
  • CHD mortality as the primary outcome, with statistical adjustments for various risk factors.

Main Results:

  • No significant association was found between arginine intake and CHD mortality.
  • Relative risks for medium and highest tertiles of intake were not significantly different from the lowest tertile, even after extensive adjustments.
  • After full adjustment, relative risks for medium and highest tertiles were 1.86 and 1.56, respectively, with no significant trend.

Conclusions:

  • The study does not support the hypothesis that dietary arginine intake reduces the risk of coronary heart disease mortality.
  • Findings suggest arginine consumption may not be a protective factor against CHD in this elderly male population.

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...